

Application No.: 10/810,649

Amendment dated January 11, 2006

Response to Office Action dated May 3, 2005


AMENDMENT TO CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Please cancel claims 2 and 30 without prejudice to their reentry at some later date.

Listing of Claims

1. (Currently Amended) A polyamine having the structure



wherein, n can be 0 to 8 and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, or 8-aminoctyl and R₁ is hydrogen or aliphatic amine except for propylamine when R=H, n=1 and the aminomethyl functionality is para substituted and halogenated forms thereof, and wherein said polyamine is non-symmetrical.

Application No.: 10/810,649
Amendment dated January 11, 2006
Response to Office Action dated May 3, 2005


2. (Canceled)

3. (Canceled)





4. (Canceled)

5. (Canceled)






6. (Currently Amended) The Δ polyamine selected from the group consisting of any one of claims 1 or 2 wherein said structure is that of one of the following compounds:



Application No.: 10/810,649
Amendment dated January 11, 2006
Response to Office Action dated May 3, 2005



Application No.: 10/810,649
Amendment dated January 11, 2006
Response to Office Action dated May 3, 2005



Application No.: 10/810,649
Amendment dated January 11, 2006
Response to Office Action dated May 3, 2005

7. (Currently Amended) A pharmaceutical composition comprising a polyamine according to any one of claims 1, 2 or 6 and a pharmaceutically acceptable excipient, diluent or vehicle.
8. (Currently Amended) The composition of claim 7 wherein said excipient, diluent or vehicle is pharmaceutically or cosmetically acceptable.
9. (Original) The composition of claim 7 wherein said excipient, diluent or vehicle is for topical or intra-aural administration.
10. (Original) The composition of claim 7 formulated for intravenous, subcutaneous, intramuscular, intracranial, intraperitoneal, topical, transdermal, intravaginal, intranasal, intrabronchial, intracranial, intraocular, intraaural, rectal, or parenteral administration.
11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Canceled)

Application No.: 10/810,649
Amendment dated January 11, 2006
Response to Office Action dated May 3, 2005

20. (Canceled)

21. (Canceled)

22. (Canceled)

23. (Canceled)

24. (Canceled)


25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Canceled)

29. (Previously Presented) The polyamine of claim 1 wherein said structure is



30. (Cancelled)


31. (Canceled)

32. (Previously Presented) The polyamine of claim 1 wherein is

Application No.: 10/810,649

Amendment dated January 11, 2006

Response to Office Action dated May 3, 2005



33. (Previously Presented) The polyamine of claim 1 wherein said structure is

